News and Announcements
Viralytics Ltd (ASX:VLA) – Shareholder and Investor Presentation
- Published April 03, 2013 12:07PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Viralytics Ltd (ASX:VLA) is an Australian ASX listed biotechnology cancer company focussed on developing viruses which selectively target cancer cells.
OVIERVIEW:
- Lead product is CAVATAK™ with broad anti-cancer activity
- CAVATAK™ program:
- Completed five Australian Phase 1 trials with 28 patients
- Current US Phase 2 trial in melanoma patients
- Planned Phase 1/2 UK trial in lung, prostate, bladder and melanoma cancer patients
- Potential low toxicity unlike traditional chemotherapies
- Achieved GMP manufacture
- Robust intellectual property/patent portfolio
- Big Pharma interest: 2011 US$1.0 billion Amgen/Biovex deal
- One of only 2 listed oncolytic virus companies globally
- Experienced Board/Management and Scientific team
To read the full ASX announcement, please download the document below.
Company Updates
IPO Bound: The Strategic Edge Guiding Australian Investors to India’s Next Unicorns
Uncover Creek Partners’ strategic vision for Australian investors in India’s booming economy. From IPO-bound deals to pioneering tech exchange, this playbook reveals how to navigate and profit from a market set to hit $7 trillion.
Navigating the Market Inflection Point: Exclusive Investor & Founder Meetups Across Australia
The market is at a genuine inflection point in mid-2025, with conflicting signals from AI breakthroughs and geopolitical shifts. This blog announces exclusive, intimate investor and founder meetups across Australia, designed to cut through the noise, reveal unfiltered truths about the H2 2025 outlook, and map the “smart money migration” to position participants for strategic advantage.
Bridging the Gap: Why Australian Capital is Crucial for India’s Trillion-Dollar Growth Story
Australia’s substantial savings pool is meeting India’s explosive growth. Learn how Creek Partners is building the crucial bridge for investors seeking to tap into India’s projected $7 trillion economy and its vibrant venture capital ecosystem.
Backed By Leading Investment Groups and Family Offices
